2,572,193 Shares in DexCom, Inc. $DXCM Purchased by Legal & General Group Plc

Legal & General Group Plc purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,572,193 shares of the medical device company’s stock, valued at approximately $173,237,000. Legal & General Group Plc owned 0.68% of DexCom as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of DXCM. Reflection Asset Management purchased a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the first quarter valued at $25,000. MCF Advisors LLC purchased a new position in DexCom in the fourth quarter valued at $32,000. Wellington Grp LLC grew its stake in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares in the last quarter. Finally, DV Equities LLC acquired a new position in DexCom during the 4th quarter worth $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DXCM. Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research note on Friday, May 1st. Wells Fargo & Company raised their target price on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target for the company. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 price target (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares in the company, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,035 shares of company stock worth $5,446,673 in the last ninety days. Company insiders own 0.28% of the company’s stock.

DexCom Trading Down 0.2%

DXCM opened at $88.96 on Thursday. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The company has a market cap of $33.57 billion, a P/E ratio of 35.16, a PEG ratio of 1.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The business’s 50-day simple moving average is $78.50 and its 200-day simple moving average is $71.33.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the company earned $0.48 EPS. As a group, equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.